「智冉医疗」再获3亿元A+轮融资，2026计划启动规模化注册临床试验

Group 1 - The core viewpoint of the article is that Zhiran Medical, a company specializing in invasive brain-machine interfaces, has secured 300 million yuan in A+ round financing, led by Zhongke Chuangxing, with participation from multiple existing investors, indicating strong confidence in the company's capabilities [1] - The funding will primarily be used to advance large-scale clinical trials and iterate high-throughput flexible brain-machine interface products, accelerating the clinical application of invasive brain-machine interface technology [1] - The founder and CEO of Zhiran Medical, Song Qi, emphasized the company's commitment to invasive brain-machine interfaces, highlighting the team's deep technical accumulation and the potential for efficient human-machine information exchange [1] Group 2 - Zhiran Medical has developed a high-throughput "stretchable flexible electrode" that can dynamically follow the brain's movements, ensuring long-term stability after implantation, and causing less mechanical damage to brain tissue compared to traditional linear electrodes [2] - The company has also established a nearly 2000 square meter clinical-grade micro-nano processing workshop and GMP-standard assembly workshop, achieving full-chain autonomy for clinical-grade products [3] - In terms of clinical trials, Zhiran Medical plans to complete clinical implantation of a high-throughput invasive brain-machine interface product with over 100 channels by 2025, with a large-scale registration clinical trial planned for 2026 [3] Group 3 - The national "14th Five-Year Plan" includes "brain-machine interfaces" as one of the six future industries, with various regions establishing special funds worth billions for brain-machine interface and neuroscience projects [4] - In 2025, the National Healthcare Security Administration will release guidelines to establish independent charging items for various brain-machine interface services, reflecting strong support for the development of the brain-machine interface industry [4] - Companies with invasive brain-machine interface platform capabilities are expected to accelerate the application of these technologies [4]